Atezolizumab monotherapy beneficial for non-small cell lung cancer ineligible for platinum-based chemo

by

For patients with non-small cell lung cancer (NSCLC) ineligible for platinum-based chemotherapy, first-line atezolizumab monotherapy is associated with improved overall survival compared to single-agent chemotherapy, according to a study published online Aug. 5 in The Lancet.

Leave A Comment

Your email address will not be published. Required fields are marked *